Find → Understand → Decide
rituximab
Discovery priority: MEDIUM · POSSIBLE / INVESTIGATE
Discovery priority ≠ investment recommendation. These are observation labels, not verified canonical products. Buyer qualification: UNKNOWN.
Why investigate?
Why stranded (event context): inadequate public evidence; supply failure
Why now: Historical lead requires current reconfirmation; no fresh transaction catalyst established
Company/trial failed before biology? UNKNOWN
Biology implicated: UNCLEAR · Failure context: CMC/OPERATIONS
MODEL INFERENCE · LOW confidence. Explicit asset-linked program event or documented experimental trial arm, stop scope, dated recency and biological cautions; no publication count or buyer-gate input.
Current control: UNKNOWN · Restart: UNKNOWN · Development reuse: UNKNOWN
Next diligence: Confirm present program status and exact product identity, then trace scoped rights/data/CMC and review arm-level human outcomes.
Existing buyer gates
Human Signal: UNKNOWN
Cheap Truth: UNKNOWN
Clean Rights: UNKNOWN
Market Pull: UNKNOWN
No event or publication count supplies missing gate evidence. Existing reviewed opportunities remain in their original records.
Evidence timeline
2025-05-06 · trial:NCT00550342
Registry update date, not proven program-stop date
SOURCE TEXT · Exact source
Problems with drug supply
Trial reason is not attributed to every intervention; comparator/combination context needs review.
Interpretation: supply failure · AUTO_INFERRED · MEDIUM
Provenance and retrieval scope
{
"hash": "e43f1dc624306cc4b9273ee189cc01a15ee71f71288dc14eba1b23095b5215eb",
"metadata": {
"complete": false,
"content_hash": "12dba2f64d20d48c47f4c2e04478803287ca92675724e452ceace13362b9457a",
"failed": false,
"last_checked": 1790026982.205955,
"last_success": 1790026982.205955,
"live_verified": true,
"scope": "AREA[OverallStatus]WITHDRAWN AND AREA[StartDate]RANGE[2000-01-01,2014-12-31] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL)"
},
"path": "protocolSection.armsInterventionsModule.interventions",
"raw_hash": "12dba2f64d20d48c47f4c2e04478803287ca92675724e452ceace13362b9457a",
"raw_path": "research/obz7_sources/12dba2f64d20d48c47f4c2e04478803287ca92675724e452ceace13362b9457a.json",
"request_params": {
"countTotal": "true",
"format": "json",
"pageSize": 100,
"query.term": "AREA[OverallStatus]WITHDRAWN AND AREA[StartDate]RANGE[2000-01-01,2014-12-31] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL)",
"sort": "LastUpdatePostDate:desc"
},
"request_url": "https://clinicaltrials.gov/api/v2/studies",
"type": "clinicaltrials",
"url": "https://clinicaltrials.gov/study/NCT00550342"
}2026-09-01 · trial:NCT05279300
Registry update date, not proven program-stop date
SOURCE TEXT · Exact source
The sponsor is temporarily pausing the trial to evaluate existing clinical data for long-term benefit-risk and optimize doses and dosing schedule.
Trial reason is not attributed to every intervention; comparator/combination context needs review.
Interpretation: inadequate public evidence · AUTO_INFERRED · MEDIUM
Provenance and retrieval scope
{
"hash": "681632d0d1af78033f82c142b635346be23966967b34adbf55d33ee198490218",
"metadata": {
"complete": false,
"content_hash": "2ca1679dad0f3f17150af6bd4f23c7bb11e653d2dd78fd7c22183dc1902caeed",
"failed": false,
"last_checked": 1790026985.182528,
"last_success": 1790026985.182528,
"live_verified": true,
"scope": "AREA[OverallStatus]SUSPENDED AND AREA[StartDate]RANGE[2015-01-01,2026-09-21] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL)"
},
"path": "protocolSection.armsInterventionsModule.interventions",
"raw_hash": "2ca1679dad0f3f17150af6bd4f23c7bb11e653d2dd78fd7c22183dc1902caeed",
"raw_path": "research/obz7_sources/2ca1679dad0f3f17150af6bd4f23c7bb11e653d2dd78fd7c22183dc1902caeed.json",
"request_params": {
"countTotal": "true",
"format": "json",
"pageSize": 100,
"query.term": "AREA[OverallStatus]SUSPENDED AND AREA[StartDate]RANGE[2015-01-01,2026-09-21] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL)",
"sort": "LastUpdatePostDate:desc"
},
"request_url": "https://clinicaltrials.gov/api/v2/studies",
"type": "clinicaltrials",
"url": "https://clinicaltrials.gov/study/NCT05279300"
}Freshness is claim-specific
Fetching an old filing today does not establish current ownership or program status.
pipeline · PARTIAL · Not independently refreshed for current scoped claim · checked UNKNOWN
sec · PARTIAL · Not independently refreshed for current scoped claim · checked UNKNOWN
rights · PARTIAL · Not independently refreshed for current scoped claim · checked UNKNOWN
contact · PARTIAL · Not independently refreshed for current scoped claim · checked UNKNOWN
patent_assignment · PARTIAL · Not independently refreshed for current scoped claim · checked UNKNOWN
clinicaltrials · STALE · AREA[OverallStatus]WITHDRAWN AND AREA[StartDate]RANGE[2000-01-01,2014-12-31] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL) · checked 2026-09-21T21:43:02.205955+00:00
clinicaltrials · STALE · AREA[OverallStatus]SUSPENDED AND AREA[StartDate]RANGE[2015-01-01,2026-09-21] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL) · checked 2026-09-21T21:43:05.182528+00:00
Registry observations (4)
NCT00550342 · WITHDRAWN · PHASE2 · Focal Segmental Glomerulosclerosis (FSGS) · Trial sponsor National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Reported aliases: Rituxan. Identity, treatment role and exposure require review.
NCT05279300 · SUSPENDED · PHASE1 · Advanced Solid Tumor; Advanced Lymphoma · Trial sponsor CStone Pharmaceuticals
Reported aliases: None. Identity, treatment role and exposure require review.
NCT01842386 · COMPLETED · PHASE1 · Pulmonary Alveolar Proteinosis (PAP); Severe Mucocutaneous Candidiasis · Trial sponsor National Institute of Allergy and Infectious Diseases (NIAID)
Reported aliases: None. Identity, treatment role and exposure require review.
NCT01135641 · COMPLETED · PHASE2 · Graft Versus Host Disease · Trial sponsor Nantes University Hospital
Reported aliases: None. Identity, treatment role and exposure require review.